SCHEMBL25025307

SCHEMBL25025307

C[C@@H]1NCCn2nc(-c3ccc(F)c(C(F)(F)F)c3)c(-n3ccn(-c4ccc5c(cnn5C)c4F)c3=O)c21

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 6/20 0.32
▸ SIGMAR1 Q99720 1/20 0.32
▸ MTOR P42345 2/20 0.32
▸ RPTOR Q8N122 1/20 0.32
▸ MLST8 Q9BVC4 1/20 0.32
▸ GRIN1 Q05586 2/20 0.31
▸ GRIN2B Q13224 2/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ PIK3CD O00329 1/20 0.31
▸ CSNK2A2 P19784 1/20 0.31
▸ FECH P22830 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ CLK1 P49759 1/20 0.31
▸ GSK3A P49840 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ MELK Q14680 1/20 0.31
▸ MYLK3 Q32MK0 1/20 0.31
▸ PIK3C3 Q8NEB9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25024870 1.00 GLP1R (0.32) GLP1RSIGMAR1MTORRPTORMLST8
SCHEMBL25024765 0.91 GLP1R (0.37) GLP1RGRIN1GRIN2B
SCHEMBL25025161 0.91 GLP1R (0.37) GLP1RGRIN1GRIN2B
SCHEMBL25024760 0.91 GLP1R (0.37) GLP1RGRIN1GRIN2B
SCHEMBL25025283 0.90 GLP1R (0.32) GLP1R
SCHEMBL25024770 0.90 GLP1R (0.32) GLP1R
SCHEMBL25023797 0.90 GLP1R (0.32) GLP1R
SCHEMBL25025186 0.88 GLP1R (0.32) GLP1R
SCHEMBL25024762 0.88 GLP1R (0.32) GLP1R
SCHEMBL25025165 0.88 GLP1R (0.32) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 — — US disclosed
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 — — US disclosed
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-02-21 — — US disclosed
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME ECCOGENE INC. 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 GLP1R 1/4885SIGMAR1 1094/4885MTOR 1032/4885
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME GLP1R, SLC5A1, GIPR GLP1R 1/4885SIGMAR1 1548/4885MTOR 552/4885
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 GLP1R 1/4885SIGMAR1 1094/4885MTOR 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback